METHOD

MSIsensor-pro: Fast, Accurate, and Matched-normal-sample-free Detection of Microsatellite Instability

Peng Jia¹,², Xiaofei Yang²,³, Li Guo¹,²,⁴, Bowen Liu¹,², Jiadong Lin¹,²,⁵, Hao Liang¹,², Jianyong Sun⁶, Chengsheng Zhang⁷,⁸, Kai Ye¹,²,⁴,⁹,*

¹ School of Automation Science and Engineering, Faculty of Electronic and Information Engineering, Xi'an Jiaotong University, Xi'an 710049, China
² MOE Key Laboratory for Intelligent Networks & Networks Security, Faculty of Electronic and Information Engineering, Xi'an Jiaotong University, Xi'an 710049, China
³ School of Computer Science and Technology, Faculty of Electronic and Information Engineering, Xi'an Jiaotong University, Xi'an 710049, China
⁴ School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, China
⁵ Leiden Institute of Advanced Computer Science, Leiden University, Leiden 2311 ZE, Netherlands
⁶ School of Mathematics and Statistics, Xi'an Jiaotong University, Xi'an 710049, China
⁷ Leiden Institute of Advanced Computer Science, Leiden University, Leiden 2311 ZE, Netherlands
⁸ School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, China
⁹ Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA

Received 3 February 2020; revised 22 February 2020; accepted 25 February 2020
Available online 12 March 2020

Handled by Song Liu

KEYWORDS
Microsatellite; Polymerase slippage; Multinomial distribution; Microsatellite instability; Tumor

Abstract Microsatellite instability (MSI) is a key biomarker for cancer therapy and prognosis. Traditional experimental assays are laborious and time-consuming, and next-generation sequencing-based computational methods do not work on leukemia samples, paraffin-embedded samples, or patient-derived xenografts/organoids, due to the requirement of matched normal samples. Herein, we developed MSIsensor-pro, an open-source single sample MSI scoring method for research and clinical applications. MSIsensor-pro introduces a multinomial distribution model to quantify polymerase slippages for each tumor sample and a discriminative site selection method to enable MSI detection without matched normal samples. We demonstrate that MSIsensor-pro is an ultrafast, accurate, and robust MSI calling method. Using samples with various sequencing depths and tumor purities, MSIsensor-pro significantly outperformed the current leading methods in both accuracy.
and computational cost. MSIsensor-pro is available at https://github.com/xjtu-omics/msisensor-pro and free for non-commercial use, while a commercial license is provided upon request.

**Introduction**

Microsatellite instability (MSI) is a form of hypermutation in the microsatellites of malignancies due to a deficient DNA mismatch repair (MMR) system [1]. Significant proportions of tumor samples with MSI status are observed in colorectal cancer (CRC), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC) [2,3]. Given that MSI is an important molecular phenotype for cancers and a key biomarker for cancer immunotherapy [4–6], two gold standard detection methods, MSI-PCR and MSI-IHC, are widely used for identifying MSI clinically [7,8]. However, both methods are laborious, time-consuming, and expensive [7,8]. Recently, several next-generation-sequencing (NGS)-based methods have been developed, which show improved time and cost efficiency, and are highly consistent with both gold standards [2,3,9–13]. For instance, MSIsensor [10], an FDA-authorized MSI detection solution based on MSK-IMPACT [14], achieved 99.4% concordance and high sensitivity [15]. However, these NGS methods have several limitations, such as requiring matched normal samples as control (sometimes inaccessible), computational expense, and being affected by low sequencing depths and low tumor purities [7]. Particularly, due to the requirement of matched normal samples, NGS-based methods do not work on leukemia samples, paraffin embedded samples or patient-derived xenografts/organoids.

A hallmark of MSI is the enrichment of insertions or deletions in microsatellite regions initiated by polymerase slippage [16,17] (Figure S1), which we have argued is an iterative process and described using a multinomial distribution (MND) model [18] (Figure S2), providing promising improvements for MSI detection efficacy using NGS data. Here, we report a novel MSI calling method, MSIsensor-pro, which addresses the aforementioned limitations of current NGS-based MSI detection tools by applying an MND model to capture the intrinsic properties of polymerase slippages in a single sample. We demonstrated that MSIsensor-pro is an ultrafast, accurate, and normal sample-free MSI calling method. Moreover, it outperforms all current MSI detection methods and is robust for samples with various sequencing depths, tumor purities, and target sequencing regions.

**Method**

**Data preprocessing**

Whole-exome sequencing data and clinical MSI status of 1532 tumor–normal pairs were downloaded from The Cancer Genome Atlas (TCGA) [18]. The sequencing data were aligned against a human reference genome (GRCh38), and MSI was determined using the gold standards [19]. The scan module (default parameters) in MSIsensor [10] was used to retrieve the microsatellite regions from the human reference genome. Then, the allelic distribution of each microsatellite for each sample was extracted and used in subsequent analyses.

**Multinomial distribution model for polymerase slippage**

To detect MSI without matched normal samples, we evaluated the stability of microsatellites using single samples. Based on the characteristics of allelic distribution of microsatellites in normal samples (Figures S1 and S2), we proposed that the polymerase slippage during DNA replication is an iterative process and that each step is independently accumulative. Therefore, we use multinomial distribution to model the slippage process in microsatellite sites. We use variable $x$ to denote hysteresis synthesis (causing deletions; $x = 0$), pre-synthesis (causing insertions; $x = 2$), and normal synthesis ($x = 1$) of each step of repeat unit synthesis, and the corresponding probabilities are denoted by $p$, $q$, and $1 - p - q$, respectively. Then, $x$ is subjected to a multinoulli distribution, and the probability distribution function is as follows:

$$pro(x|p, q) = \begin{cases} 
p & \text{if } x = 0 \\
1 - p - q & \text{if } x = 1 \\
q & \text{if } x = 2 
\end{cases}$$

(1)

Thus, for a microsatellite site with $n$ repeats on the reference genome, we assume that $y$ is the repeat length observed from the data. Therefore, we have:

$$y = \sum_{i=1}^{n} x_i$$

(2)

and the probability distribution function of $y$ is:

$$pro(y|p, q) = \begin{cases} 
pro_{ND} + \Delta & (y \leq n) \\
pro_{SL} + \Delta & (y > n)
\end{cases}$$

(3)

where:

$$pro_{ND} = C_{y}^{n-y} \prod_{i=1}^{y} pro(x_i = 1) \prod_{j=y+1}^{n} pro(x_i = 0)$$

(4)

$$pro_{SL} = C_{y}^{2n-2} \prod_{i=1}^{2n-y-1} pro(x_i = 1) \prod_{j=2n-y+1}^{2n} pro(x_i = 2)$$

(5)

Here, $pro_{ND}$ and $pro_{SL}$ denote the probability of acquiring the observed repeat length due to deletion and insertion, respectively, with the minimum number of steps, while $\Delta$ is the probability of using more steps. Since $\Delta$ is much smaller and difficult to calculate, we ignore it in practice to preserve computational resources. For a microsatellite region spanned by $m$ reads, we denote the observed repeat length as $y_1, y_2, \ldots, y_i, \ldots, y_m$ and its distribution as $Y = \{y_1, y_2, \ldots, y_i, \ldots, y_m\}$. Based on $Y$, we use the maximum likelihood estimation to compute $p$ and $q$ in Equation (6).

$$L(Y|p, q) = \prod_{i=1}^{m} pro(y_i)$$

(6)
Finally, \( p \) and \( q \) can be estimated as follows:

\[
\begin{align*}
    p &= \frac{\sum_{i=1}^{n} (\mu_i - \mu)}{nm} \\
    q &= \frac{\sum_{i=1}^{n} (\nu_i - \nu)}{nm}
\end{align*}
\]

(7)

The values of \( p \) and \( q \) are positively correlated with the magnitude of polymerase slippages.

Validation of the MND model

To evaluate how well parameters \( p \) and \( q \) from the MND mimic polymerase slippages for microsatellites with various repeat lengths, we randomly selected 27,200 microsatellites from normal control samples of three cancer types in TCGA and estimated the parameters \( p \) and \( q \) for each microsatellite site. Then, the calculated \( p \) and \( q \) values (also known as the probabilities of deletion and insertion) were used to simulate allele length distribution. The sites with no significant difference (\( P < 0.05 \), Kolmogorov–Smirnov test) between real and simulated distribution are defined as fitted sites. Then, the percentage of fitted sites to all test sites was used to evaluate the fitness of the MND model. To investigate polymerase slippages in tumor samples, we estimated \( p \) and \( q \) for 1532 TCGA tumor samples and compared the differences between MSI and microsatellite stable (MSS) samples. In this study, only samples with status of MSI-H as determined by MSI-PCR are classified as MSI samples, whereas cancer samples with status MSS or MSI-L are classified as MSS samples, as reported previously [3]. We found that \( p \) discriminates between MSI and MSS samples while \( q \) does not, indicating that \( p \) is an effective metric for MSI classification.

MSI calling of MSIsensor-pro

We used \( p \) (probability of deletion) from the MND model to evaluate the stability of microsatellites. To distinguish unstable sites from stable ones we determined the mean (\( \mu_i \)) and standard deviation (\( \sigma_i \)) of \( p \) in the \( i \)-th microsatellite site in normal samples. Specifically, a microsatellite is classified as unstable with \( p > \mu_i + 3\sigma_i \). We used 1532 normal control samples from three cancer types to build the baseline. The MSI score, defined as the percentage of unstable sites within all detected sites in a sample, is used for MSI calling.

Discriminative microsatellite site selection

To find discriminative microsatellite (DMS) sites for MSI calling, we computed the contribution of each site to MSI classification. For a given microsatellite site, the parameter \( p \) was used for MSI classification, and then the area under the receiver operating characteristic curve (AUC) was calculated to evaluate the contribution of this site to MSI calling. Finally, sites with \( AUC > 0.65 \) were defined as DMS sites and used for MSI calling. In this study, 340 TCGA samples were used to discover DMS sites, and all 1532 samples were used to test the performance of MSIsensor-pro.

MSIsensor-pro performance evaluation

To assess the performance of MSIsensor-pro, we benchmarked MSIsensor-pro against MSIsensor [10], MANTIS [12], and mSINGS [11] using the 1532 TCGA tumor samples. The MSI score was used to rank sites for MSI classification, and AUC was used to evaluate the performance of each method (File S1). CPU usage, memory, and runtime for all these methods were tested on a TCGA sample, TCGA-AD-A5EJ, using a Linux machine running Ubuntu18.04 OS with Intel(R) Core i7-7700 CPU @ 3.40 GHz and 32-GB memory.

To compare the performances of the four methods on samples with low sequencing depths or low tumor purities, we used 178 CRC (78 MSI and 100 MSS) tumor–normal paired samples from TCGA to simulate test data. We downsampled the raw sequencing data to 5×, 10×, 20×, 40×, 60×, and 80× sequencing depths and mixed different proportions of tumor and normal sequencing data to generate samples with tumor purities ranging from 5% to 80%. We called MSI for all simulated data and calculated the AUC for each method. To assess the performance of MSIsensor-pro using fewer sites, we selected microsatellite sets containing the top 1, 2, 5, 10, 20, 50, 100, 200, 500, and 1000 DMS sites for MSI calling. In addition, we randomly selected various number of microsatellites from DMS sites for MSI calling to examine the number of sites sufficient for MSI calling by MSIsensor-pro.

Results

Evaluation of MND model

To quantitatively describe the polymerase slippages present in a single sample, we first examined the allele length distributions of 27,200 microsatellites in 1532 normal samples from TCGA [18] (Tables S1 and S2; Method). The distributions flattened (the variances became larger and the modes deviated from expectation) with increases in the repeat length of microsatellites in the reference genome (Figure 1A), suggesting that polymerase slippage could be an iterative process. We proposed that polymerase slippages are independently cumulative in the DNA replication process and could be modeled by the MND model. Here, we used \( p \) and \( q \) to denote the probabilities of hysteresis synthesis (causing deletions) and pre-synthesis (causing insertions), respectively, for each replication unit (Figure S2). We next estimated \( p \) and \( q \) for each microsatellite to quantify the polymerase slippage in a given allele length distribution.

To explore the characteristics of \( p \) and \( q \) in the MND model, we applied the model to 1532 TCGA normal samples. We obtained a total of 11,666 microsatellites with sufficient read coverage (>20×) in more than half of the samples for subsequent study (Tables S1 and S2). We found that the average probability of hysteresis synthesis, \( p \), is significantly larger (\( P < 0.05 \), Wilcoxon rank-sum test) than that of presynthesis, \( q \) (Figure S3), at these sites, indicating that polymerase slippages tend to cause more deletions than insertions at microsatellites, confirming previous reports [2,17]. To evaluate the power of our MND model for describing polymerase slippages in DNA replication, we simulated the allele length distributions at each microsatellite site with their corresponding
computed $p$ and $q$ values, and compared them with the observed values from sequencing data. We found that the allele length distributions of the simulated data were consistent with those of observed values at 91.97% of microsatellites and the similarities between the two distributions decreased with increasing repeat length (Figures 1B and S4 and S5), confirming that the MND model is capable of describing polymerase slippages at microsatellite sites.

Performance of MSIsensor-pro

Based on the MND model, we developed a method called MSIsensor-pro to detect MSI. We applied our MND model to 1532 TCGA tumor samples with clinical MSI status and obtained their $p$ and $q$ values at each microsatellite site. We found that the MSI samples have significantly larger $p$ values than MSS samples ($P < 2 \times 10^{-16}$), while $q$ values in the MSI and MSS samples are not significantly different (Figures 1C, D and S6–S9). Thus, it is conceivable that either the higher incidence of polymerase slippages or failure to fix deletion errors, and therefore, the greater instability of microsatellites in MSI as opposed to MSS, could be attributed to more deletions rather than insertions [9]. Therefore, parameter $p$ could evaluate the stability of each microsatellite site. MSIsensor-pro classifies the $i$-th microsatellite as unstable when its $p$ is larger than $\mu_i + 3 \sigma_i$, in which $\mu_i$ and $\sigma_i$ are the mean and standard deviation, respectively, of $p$ in 1532 normal samples at the $i$-th microsatellite. The fraction of unstable sites in a given microsatellite set is used to score MSI in a tumor sample (Figure S10 and Methods).

To assess the performance of MSIsensor-pro in terms of accuracy and computational cost, we compared MSIsensor-pro against MSIsensor [10], MANTIS [12], and mSINGS [11]. Among them, MSIsensor and MANTIS require tumor–normal-paired samples, whereas mSINGS requires tumor-only samples (Tables S1 and S2; File S2). First, we applied MSIsensor-pro to 1532 TCGA tumor samples based on 11,666 preselected microsatellites to detect MSI and then compared the MSI detection accuracy with the other three methods in the same samples using AUC. We noticed that even without matched normal samples, AUC values of MSIsensor-pro are comparable to those of MSIsensor and MANTIS, but much higher than those of mSINGS (Table 1 and Table S3).

Sequencing data from samples with low sequencing coverage or low tumor purities are common challenges for robust MSI detection in clinical applications [15]. To indicate the robustness of MSIsensor-pro for various sequencing depths or tumor purities, we evaluated the performance of all four aforementioned methods on 178 CRC samples (78 MSI and 100 MSS) in both original settings and varied sequencing depths or tumor purities. Multiple sequencing depths ($5 \times, 10 \times, 20 \times, 40 \times, 60 \times$, and $80 \times$) resulted from simulating and downsampling the original data, while various tumor purities (5%, 10%, 20%, 40%, 60%, and 80%) were simulated by mixing the tumor and matched normal samples (Method). Across samples of diverse depths and tumor purities, AUC values of MSIsensor-pro, MSIsensor, and MANTIS were all much higher than those of mSINGS. Notably, MSIsensor-pro, requiring tumor samples only, achieved performance comparable to that of MSIsensor and MANTIS, both of

---

**Figure 1** MND model of polymerase slippages

A. Allele length distribution of homopolymers in normal samples. The gray vertical lines represent the repeat lengths in the human reference genome (GRCh38). B. The fitness of the MND model for polymerase slippages. The values on the top of boxplots represent the percentages of sites fitted ($P < 0.05$, Kolmogorov–Smirnov test) to the MND model at the respective repeat lengths. C. Dot plots for the means of parameter $p$ (probability of deletion) in the MND model using 326 MSI and 1206 MSS samples (11,666 sites). D. Dot plots for the means of parameter $q$ (probability of insertion) in the MND model using 326 MSI and 1206 MSS samples (11,666 sites). Dots are color-scaled according to the number of sites as shown by the color key. Dots near the diagonal lines represent sites indistinguishable between MSI and MSS. MND, multinomial distribution; MSI, microsatellite instability; MSS, microsatellite stable.
which require normal–tumor-paired samples to call MSI (Figure 2A; Tables S4–S7). These results confirm the robustness of MSIsensor-pro and indicate that MSIsensor-pro can achieve high accuracy on samples with low sequencing depth (e.g., 20 × ) or low tumor purity (e.g., 40%).

To further evaluate the computational performances of all these four methods, we called MSI for a TCGA sample (TCGA-AD-A5EJ (35-GB tumor and 12-GB normal bam files)) using these four methods on a Linux machine running Ubuntu18.04 OS with Intel(R) Core (TM) i5-7500 CPU@3.40 GHz and 32-GB memory. MSIsensor-pro and MSIsensor required only 4 min and 15 min, respectively, thus performing significantly faster than mSINGS (94 min) and MANTIS (119 min). In addition, MSIsensor-pro consumed much less memory than MSIsensor, mSINGS, and MANTIS (Table 2; Figures S11 and S12).

While MSIsensor-pro exhibited satisfactory all-around performance in detecting MSI using the 11,666 preselected microsatellites, these sites seemed to have an unequal contribution to MSI classifications (Figure S13). We therefore evaluated the contribution of each microsatellite based on MND parameter $p$ and identified 7698 sites (Table S8) with strong

| Method          | Input  | CRC (n = 588) | STAD (n = 412) | UCEC (n = 532) | Total (n = 1532) |
|-----------------|--------|--------------|---------------|----------------|-----------------|
| MANTIS          | T–N    | 0.983        | 1.000         | 0.993          | 0.986           |
| MSIsensor       | T–N    | 0.981        | 1.000         | 0.988          | 0.989           |
| mSINGS          | T      | 0.594        | 0.711         | 0.634          | 0.594           |
| MSIsensor-pro   | T      | 0.993        | 0.999         | 0.987          | 0.993           |
| MSIsensor-pro (DMS) | T   | 0.997        | 1.000         | 0.990          | 0.994           |

Note: For MSIsensor-pro (all), all 11,666 preselected microsatellite sites were used for MSI computation; for MSIsensor-pro (DMS), only 7698 DMS sites were used for MSI computation. AUC, area under the receiver operating characteristic curve; DMS, discriminative microsatellite; CRC, colorectal cancer; STAD, stomach adenocarcinoma; UCEC, uterine corpus endometrial carcinoma; T–N, tumor–normal paired sample; T, tumor only sample.

Figure 2  MSI calling accuracy in TCGA dataset

A. AUC for four MSI detection methods across various sequencing depths (ranging from 5 × to 100 × ; left) and tumor purities (ranging from 5% to 100%; right) in 78 MSI and 100 randomly selected MSS CRC samples from TCGA. The methods tested include MSIsensor-pro, MSIsensor, MANTIS, and mSINGS. MSIsensor-pro was tested using all 11,666 preselected sites for MSIsensor-pro (all) and 7698 DMS sites for MSIsensor-pro (DMS), respectively. B. AUC of MSIsensor-pro using top 1–1000 contributing DMS sites for 1532 TCGA samples in total and for individual cancer types of CRC, STAD, and UCEC. AUC values approach a plateau with the top 20 contributing sites. C. AUC of MSIsensor-pro using 1–1000 randomly-selected DMS sites for 1532 TCGA samples. AUC values approach a plateau with 50 randomly-selected sites. These random tests were run 10 times. Data points are color-coded according to the number of DMS sites randomly selected. The black point is the mean of 10 AUC values for each group, with the top line and bottom lines of each bar representing the maximum and minimum of 10 AUCs, respectively. AUC, area under the receiver operating characteristic curve; DMS, discriminative microsatellite; CRC, colorectal cancer; STAD, stomach adenocarcinoma; UCEC, uterine corpus endometrial carcinoma. T–N, tumor–normal paired; T, tumor only.
various target sequencing panels with as few as 50 sites (Figures 2C and S14; Tables S9 and S10).

For data of different tumor purities using DMS sites, MSIsensor-pro exhibited performance comparable to those of other tumor–normal-paired methods for tumor purities of over 40%. However, for lower tumor purities (<40%), although the performances of all methods decreased, the performance of MSIsensor-pro on DMS sites remained superior to all other methods examined (Figure 2A; Tables S6 and S7).

Since only a portion of all 11,666 sites (DMS sites) were sufficient for high performance MSI calling by MSIsensor-pro, we wonder whether an even smaller subset of DMS sites would be adequate for MSIsensor-pro to achieve similar performance, which would reduce time and cost in practical clinical applications. We therefore assessed the MSI calling performance of MSIsensor-pro on microsatellite sets from single type of tumor samples or in combination containing the top 1, 2, 5, 10, 20, 50, 100, 200, 500, and 1000 DMS sites based on their contributions. We found that even with only 1 top site, MSIsensor-pro achieved AUC values ranging 0.92–0.96 (Figure 2B; Tables S9 and S10). The performance improved with increases in the number of top sites and reached a plateau when using the top 20 sites (0.98 AUC). In addition, by testing MSIsensor-pro performance on various number of randomly selected DMS sites, we sought to identify small panels of DMS sites that are potentially effective at robust MSI calling. Indeed, we found that the AUC values for MSI detection steadily increased with growing number of randomly-selected DMS sites. When as few as 50 random sites were used, the AUC was approximately 0.98 and remained stable. Taken together, these results suggest that MSIsensor-pro could be applied to various target sequencing panels with as few as 50 sites (Figures 2C and S14; Tables S9 and S10).

Discussion

In this study, we completely redesigned the MSI scoring strategy. By incorporating a MND model for polymerase slippage, MSIsensor-pro scores MSI on tumor samples without matched normal controls, enabling detection of MSI status on patient-derived xenografts/organoids, leukemia, and paraffin-embedded samples. In addition, MSIsensor-pro is able to score MSI using as few as 50 microsatellite sites (Figure 2C), indicating its potential to compute MSI status in cancer gene panels, stool DNA, and circulating tumor DNA from liquid biopsy samples.

MSIsensor-pro exhibits remarkable advantages in terms of both accuracy and computational cost, compared to the current leading NGS-based MSI scoring methods tested in this study, especially when processing samples with low sequencing depths or low tumor purities (Figure 2). MSIsensor-pro improves AUC values of MSI classification with tumor only samples from 0.594 (mSINGS) to 0.994 in 1532 TCGA samples (Table 1). We have also demonstrated the advantageous performance of MSIsensor-pro using data with various tumor purities (Figure 2A). We will further optimize our approach to integrate tumor purity information to our MND model for polymerase slippage.

In addition to these methodological analyses, we also examine the properties of DMS sites and find that these sites are closer to splicing sites and located in genes with higher expression than the other sites (Figures S15–S17), indicating potential roles of DMS sites in tumorigenesis.

Table 2  Peak RAM and runtime used by four MSI detection methods for the sample TCGA-AD-A5EJ

| Method          | Input | Peak RAM (GB) | Runtime (min) |
|-----------------|-------|---------------|---------------|
| MANTIS          | T-N   | 3.712         | 119           |
| MSIsensor       | T-N   | 0.576         | 15            |
| mSINGS          | T     | 2.592         | 94            |
| MSIsensor-pro (all) | T     | 0.032         | 4             |
| MSIsensor-pro (DMS) | T   | 0.032         | 3             |

Note: Runtime is evaluated by wall clock time.

MSIsensor-pro is available at [https://github.com/xjtu-omics/msisensor-pro](https://github.com/xjtu-omics/msisensor-pro) with help documentation and demo data. It is free for non-commercial use by academic, government, and non-profit/not-for-profit institutions. A commercial version of the software is available and licensed through Xi’an Jiaotong University. For more information, please contact kaiye@xjtu.edu.cn.

Data availability

Primary sequencing data, gold standard MSI status, and RNA expression data can be downloaded from TCGA Research Network ([http://cancergenome.nih.gov/](http://cancergenome.nih.gov/)). All results generated by this study are available in Supplementary materials from the article.

Authors’ contributions

KY conceived of, designed, and supervised the study; PJ, BL, and JS developed the multinomial distribution model for polymerase slippage estimation; PJ and HL implemented the source code of MSIsensor-pro; PJ evaluated the performances of MSIsensor-pro and the other three MSI detection methods. PJ, JL, XY, LG, CZ, and KY wrote the manuscript. All authors contributed to critical revision of the manuscript, read and approved the final version.
Competing interests

The authors declare no competing financial interests.

Acknowledgments

We thank Beifang Niu, Tingjie Wang, Yongyong Kang, Xiujuan Li, and Shenghan Gao for helpful discussions regarding data analysis and Jing Hai for administrative and technical support. This study was supported by the National Key R&D Program of China (Grant Nos. 2018YFC0910400 and 2017YFC0907500), the National Natural Science Foundation of China (Grant Nos. 31671372, 61702406, 31701739, and 31970317), the National Science and Technology Major Project of China (Grant No. 2018ZX10302205), as well as the “World-Class Universities and the Characteristic Development Guidance Funds for the Central Universities” and the General Financial Grant from the China Postdoctoral Science Foundation (Grant Nos. 2017M623178 and 2017M623188).

Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.gpb.2020.02.001.

ORCID

0000-0002-3429-919X (Jia P)
0000-0002-5118-7755 (Yang X)
0000-0001-3481 (Guo L)
0000-0001-6570-1981 (Liu B)
0000-0002-8116-5901 (Lin J)
0000-0001-7987-6002 (Liang H)
0000-0002-1856 (Sun J)
0000-0002-7115 (Zhang C)
0000-0002-2851-6741 (Ye K)

References

[1] Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacol Ther 2018;189:45–62.
[2] Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 2016;22:1342–50.
[3] Cortes-Ciriano I, Lee S, Park WY, Kim TM, Park PJ. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun 2017;8:15180.
[4] Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–20.
[5] Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124–8.
[6] Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409–13.
[7] Baudrin LG, Deleuze JF, HowKit A. Molecular and computational methods for the detection of microsatellite instability in cancer. Front Oncol 2018;8:621.
[8] Janavicius R, Maturaike D, Jakubauskas A, Griskevicius L. Microsatellite instability detection by high-resolution melting analysis. Clin Chem 2010;56:1750–7.
[9] Kim TM, Laird PW, Park PJ. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell 2013;155:858–68.
[10] Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 2014;30:1015–6.
[11] Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem 2014;60:1192–9.
[12] Kauutto EA, Bonneville R, Miya J, Yu L, Krook MA, Reeser J, et al. Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. Oncotarget 2017;8:7452–63.
[13] Bonneville R, Krook MA, Kauutto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol 2017. https://doi.org/10.1200/PO.17.00073.
[14] Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 2015;17:251–64.
[15] Middha S, Zhang L, Nafa K, Jayakumaran G, Wong D, Kim HR, et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. JCO Precis Oncol 2017. https://doi.org/10.1200/PO.17.00084.
[16] Lange SS, Takata K, Wood RD. DNA polymorphisms and cancer. Nat Rev Cancer 2011;11:96–110.
[17] Leclercq S, Rivals E, Jarne P. DNA slippage occurs at microsatellite loci without minimal threshold length in humans: a comparative genomic approach. Genome Biol Evol 2010;2:325–35.
[18] The Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet 2013;45:1113–20.
[19] Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248–57.